SCHEMBL6100790

SCHEMBL6100790

COc1cc(CC(=O)Nc2ccccc2Cc2ccccc2)ccc1O

nearest known ligand 0.55

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.55
ALDH1A1 P00352 3/20 0.55
TSHR P16473 1/20 0.54
NFKB1 P19838 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
MAPT P10636 1/20 0.54
KMT2A Q03164 4/20 0.53
MEN1 O00255 3/20 0.53
POLB P06746 2/20 0.53
LMNA P02545 1/20 0.51
TRPV1 Q8NER1 1/20 0.50
BCHE P06276 1/20 0.50
ACHE P22303 1/20 0.50
GFER P55789 1/20 0.50
HPGD P15428 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6101314 0.90 KMT2A (0.55) GAAALDH1A1TSHRNFKB1TDP1
SCHEMBL6100235 0.80 BCHE (0.65) GAAALDH1A1TSHRNFKB1TDP1
SCHEMBL6101976 0.79 SNCA (0.64) GAAALDH1A1TSHRNFKB1TDP1
SCHEMBL6100957 0.79 GAA (0.52) GAAALDH1A1TSHRNFKB1TDP1
SCHEMBL6101972 0.79 SNCA (0.64) GAAALDH1A1TSHRNFKB1TDP1
SCHEMBL2925120 0.78 TRPV1 (0.70) GAAALDH1A1TSHRNFKB1TDP1
SCHEMBL6099937 0.77 ALDH1A1 (0.65) GAAALDH1A1TSHRNFKB1TDP1
SCHEMBL6099398 0.77 KMT2A (0.64) GAAALDH1A1TSHRNFKB1TDP1
SCHEMBL14298826 0.77 GAA (0.69) GAAALDH1A1TSHRNFKB1TDP1
SCHEMBL19879879 0.76 HPGD (0.60) GAAALDH1A1KMT2AMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1282640-C N-arylphenylacetamide derivatives and medicinal compositions containing same DAINIPPON PHARMACEUTICAL CO (JP) 2006-11-01 CN disclosed
US-7084176-B2 N-arylphenylacetamide derivatives and medicinal compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2006-08-01 US disclosed
US-20040248983-A1 N-arylphenylacetamide derivatives and medicinal compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-12-09 US disclosed
CN-1529692-A N-arylphenylacetamide derivatives and medicinal compositions containing same 大日本制药株式会社 2004-09-15 CN disclosed
EP-1403235-A1 N-ARYLPHENYLACETAMIDE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME Dainippon Pharmaceutical Co., Ltd. (JP) 2004-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248983-A1 N-arylphenylacetamide derivatives and medicinal compositions containing the same HRH2, CCR8, CYP2C8 GAA 4362/4885ALDH1A1 684/4885TSHR 3162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.